HOUSTON--(BUSINESS WIRE)--The Kidney Cancer Association (KCA) is pleased to announce the recipients of the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA).
Established this year, the purpose of the ADA is to promote collaboration between a clinician and a Ph.D. to propose new research that will make an immediate impact in the field of kidney cancer. The YIA seeks to encourage promising researchers in urology and clinical oncology who are planning to pursue an investigative career in kidney cancer. Two ADA recipients are granted $500,000 and four YIA recipients are granted $75,000.
An independent panel of experts conducted a scored review of all applications.
For more information visit https://www.kidneycancer.org.
A full version of the press release is available at: https://www.kidneycancer.org/news-and-events/#pressroom.
Advanced Discovery Awards
Kathleen M. Mahoney, MD, PhD - Dana-Farber Cancer Institute, Beth Israel-Deaconess Medical Center
Gordon J. Freeman, PhD - Dana-Farber Cancer Institute
Rupal S. Bhatt, MD, PhD - Beth Israel-Deaconess Medical Center
HHLA2/KIR3DL3 as a novel therapeutic immune checkpoint pathway in renal cancer
Eric Jonasch, MD - The University of Texas MD Anderson Cancer Center
Guang Peng, PhD - The University of Texas MD Anderson Cancer Center
S-phase DNA damage response links genomic instability mechanisms to anti-tumor immunity in renal cell carcinoma
Young Investigator Awards
Scott M. Haake, MD - Vanderbilt University Medical Center
Wendy Kimryn Rathmell, MD, PhD (Mentor) - Vanderbilt University Medical Center
Endogenous retrovirus expression drives immunogenicity of papillary renal cell carcinoma
Akash Kumar Kaushik, PhD - University of Texas Southwestern Medical Center
Ralph J. DeBerardinis, MD, PhD (Mentor) - University of Texas Southwestern Medical Center
In vivo glutamine metabolism in VHL and FH mutant renal cell carcinoma
Ed Reznik, PhD - Memorial Sloan Kettering Cancer Center
A. Ari Hakimi, MD (Mentor) - Memorial Sloan Kettering Cancer Center
Metabolic determinants of the tumor microenvironment and sensitivity to immunotherapy in ccRCC
Tian Zhang, MD, MHS - Duke Cancer Institute
Daniel J. George, MD (Mentor) - Duke Cancer Institute
Immune correlates of immunotherapy responses in renal cell carcinoma